ES2089600T3 - Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas. - Google Patents

Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.

Info

Publication number
ES2089600T3
ES2089600T3 ES93101842T ES93101842T ES2089600T3 ES 2089600 T3 ES2089600 T3 ES 2089600T3 ES 93101842 T ES93101842 T ES 93101842T ES 93101842 T ES93101842 T ES 93101842T ES 2089600 T3 ES2089600 T3 ES 2089600T3
Authority
ES
Spain
Prior art keywords
compounds
cell proliferation
effect
infarction
antiarrhythmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93101842T
Other languages
English (en)
Inventor
Hans-Jochen Dr Lang
Dieter Dr Mania
Andreas Dr Weichert
Wolfgang Dr Scholz
Udo Dr Albus
Heinrich Dr Englert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2089600T3 publication Critical patent/ES2089600T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/44—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Phenolic Resins Or Amino Resins (AREA)

Abstract

SE DESCRIBEN BENZOILGUANIDINAS DE LA FORMULA I CON R(1) DEFINIDO COMO R(4) ALQ(EN)IL, DONDE R(5) TIENE TAMBIEN EL SIGNIFICADO DE H. R(6) = H O C1 C4 F2P+1, ALQUIL (METIL) FINIDO ENTRE OTROS COMO R(1), ASI COMO SUS SALES TOLERABLES FARMACEUTICAMENTE. LOS COMPUESTOS I SE OBTIENEN TAMBIEN A TRAVES DE LA TRANSFORMACION DE COMPUESTOS DE LA FORMULA II CON GUANIDINA, DONDE L ES UN GRUPO SUSTITUIBLE NUCLEOFILO LIGERO. LOS COMPUESTOS I PUEDEN SER CONSIDERADOS COMO MEDICAMENTOS ANTIARRITMICOS CON COMPONENTE CARDIOPROTECTOS PARA LA PROFILAXIS DEL INFARTO O EL TRATAMIENTO DEL INFARTO ASI COMO EL TRATAMIENTO DE LA ANGINA DE PECHO DE FORMA SOBRESALIENTE, CON LO QUE INHIBEN DE FORMA PREVENTIVA LOS FENOMENOS PATOPSICOLOGICOS EN LA GENERACION DE DAÑOS INDUCIDOS ISQUEMICOS O LO EVITAN DE FORMA ACENTUADA. POR OTRA PARTE SE EVITAN POR MEDIO DE UNA ACCION INHIBIDORA FUERTE SOBRE LA PROLIFERACION DE CELULAS. PUEDEN SER UTILIZADOS ADEMAS COMO ANTIATEROSCLEROTICOS, COMO MEDIOS CONTRA LAS COMPLICACIONES TARDIAS DELA DIABETES, ENFERMEDADES DEL CANCER, ENFERMEDADES FIBROTICAS COMO FIBROSIS PULMONAR, FIBROSIS DE HIGADO, FIBROSIS DE RIÑON. SON INHIBIDORES DE ACCION COMPLETA DEL ANTIPORTADOR SODIO-PROTONES (NA + /H)
ES93101842T 1992-02-15 1993-02-05 Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas. Expired - Lifetime ES2089600T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4204575 1992-02-15

Publications (1)

Publication Number Publication Date
ES2089600T3 true ES2089600T3 (es) 1996-10-01

Family

ID=6451807

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93101842T Expired - Lifetime ES2089600T3 (es) 1992-02-15 1993-02-05 Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.

Country Status (16)

Country Link
US (1) US5373024A (es)
EP (1) EP0556674B1 (es)
JP (1) JP3523284B2 (es)
AT (1) ATE139526T1 (es)
AU (1) AU661548B2 (es)
CA (1) CA2089439C (es)
DE (1) DE59302959D1 (es)
DK (1) DK0556674T3 (es)
ES (1) ES2089600T3 (es)
FI (1) FI930601L (es)
GR (1) GR3020290T3 (es)
HU (1) HU218788B (es)
IL (1) IL104713A (es)
NO (1) NO179549C (es)
NZ (1) NZ245894A (es)
ZA (1) ZA93984B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
ATE144248T1 (de) * 1992-07-01 1996-11-15 Hoechst Ag 3,4,5-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
US5665739A (en) * 1992-12-15 1997-09-09 Hoechst Aktiengesellschaft Substituted benzoylguanidines, process and their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
DK0612723T3 (da) * 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4327244A1 (de) * 1993-08-13 1995-02-16 Hoechst Ag Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4415873A1 (de) * 1994-05-05 1995-11-09 Hoechst Ag Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4421495A1 (de) * 1994-06-20 1995-12-21 Merck Patent Gmbh Heterocyclyloxy-benzoylguanidine
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DE4430213A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Arylbenzoylguanidine
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
DE4430861A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Heterocyclyl-benzoylguanidine
DE4430916A1 (de) * 1994-08-31 1996-03-07 Merck Patent Gmbh Alkyl-benzoylguanidin-Derivate
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
DE4432101A1 (de) 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432105A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Fluoro-alkyl/alkenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
ES2094696B1 (es) * 1995-03-09 1997-09-01 Univ Alicante Aplicaciones de la halocina h7.
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ZA967800B (en) * 1995-09-20 1997-04-03 Yamanouchi Pharma Co Ltd Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
EP0765867A1 (de) * 1995-09-27 1997-04-02 Hoechst Aktiengesellschaft Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316438A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19603425A1 (de) 1996-01-31 1997-08-07 Hoechst Ag Substituierte Diaryldicarbonsäure-diguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
WO1998039300A1 (en) * 1997-03-06 1998-09-11 Toa Eiyo Ltd. CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2006215084B2 (en) * 2005-02-16 2011-03-24 Toa Eiyo Ltd. Cyclohepta(b)pyridine-3-carbonylguanidine derivative and pharmaceutical product containing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament

Also Published As

Publication number Publication date
NO179549C (no) 1996-10-30
HU9300367D0 (en) 1993-04-28
NO930510D0 (no) 1993-02-12
FI930601A7 (fi) 1993-08-16
DE59302959D1 (de) 1996-07-25
IL104713A (en) 1998-02-08
CA2089439A1 (en) 1993-08-16
GR3020290T3 (en) 1996-09-30
DK0556674T3 (da) 1996-10-14
ATE139526T1 (de) 1996-07-15
HUT65589A (en) 1994-07-28
NZ245894A (en) 1995-01-27
FI930601A0 (fi) 1993-02-11
JPH05339228A (ja) 1993-12-21
AU661548B2 (en) 1995-07-27
FI930601L (fi) 1993-08-16
AU3301593A (en) 1993-08-19
ZA93984B (en) 1993-09-20
CA2089439C (en) 2006-04-11
EP0556674B1 (de) 1996-06-19
IL104713A0 (en) 1993-06-10
HU218788B (hu) 2000-12-28
JP3523284B2 (ja) 2004-04-26
NO930510L (no) 1993-08-16
NO179549B (no) 1996-07-22
EP0556674A1 (de) 1993-08-25
US5373024A (en) 1994-12-13

Similar Documents

Publication Publication Date Title
ES2089600T3 (es) Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.
ES2192201T3 (es) Compuestos de piranona utiles para el tratamiento de infecciones retrovirales.
BR9205902A (pt) Composto e processo para preparar o mesmo, composição fungicida e processo para combater fungos
ES2094034T3 (es) Composicion antiacneica para el tratamiento simultaneo de las capas superficiales y profundas de la piel, su utilizacion.
ECSP941111A (es) Nuevas sulfonilaminopirimidinas,
KR910006225A (ko) 벤조일구아니딘, 이의 제조방법. 약제로서의 이의 용도 및 이를 함유하는 약제
ES2092729T3 (es) Benzoilguanidinas 3,4,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
EA200500804A1 (ru) Топические противоинфекционные композиции
ES2191766T3 (es) Composicion antiparasitaria para el tratamiento y la proteccion de los animales de compañia.
ES2107648T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
CO4410181A1 (es) Derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol
DE59409439D1 (de) Substituierte 1,1-dioxo-2H-1,2-benzothiazinoylguanidine mit Na+/H+-Austausch inhibierender Wirkung
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
BR8803621A (pt) Emprego de um composto,composicao e processo para o combate de insetos
ES2063097T3 (es) Inhibidor de la glicosidasa salbostatina, procedimiento para su preparacion y su empleo.
ES2118708T3 (es) Composiciones de piperidina y su preparacion y utilizacion.
KR950010887A (ko) 연골 퇴화 억제 방법
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556674

Country of ref document: ES

FG2A Definitive protection

Ref document number: 556674

Country of ref document: ES